Internal Medicine, Cardiovascular Disease · Amarillo, TX
NPI
1720076664
Since 2005
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
6200 I-40 W
Amarillo, TX, 79106
Phone (806) 354-9764
Medicare paid, 2024
$865K
10,727 services
Medicare patients, 2024
2,357
Average age 76
Drug cost, 2024
$1.9M
12,337 prescriptions
Company payments, 2023
$69.99
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joel C Osborn was code 99490 (chronic, principal, and transitional care management), 2,437 times for 254 patients. In total Joel C Osborn billed 10,727 services in 58 codes, and Medicare paid $865K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-01-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 2,437 | 254 | $46.57 | $113K |
| 93010 Electrocardiogram | Facility | 1,437 | 1,045 | $5.88 | $8,454 |
| 99214 Office E&M - Established | Office | 1,265 | 947 | $90.80 | $115K |
| 93000 Electrocardiogram | Office | 702 | 555 | $10.41 | $7,305 |
| J2785 Injection, regadenoson, 0.1 mg | Office | 701 | 174 | $5.29 | $3,710 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 664 | 76 | $46.92 | $31K |
| 99457 E&M - Miscellaneous | Office | 531 | 68 | $38.11 | $20K |
| 99454 E&M - Miscellaneous | Office | 460 | 63 | $35.84 | $16K |
| 93306 Echocardiography (TTE/TEE) | Office | 343 | 337 | $115.62 | $40K |
| 85610 Clinical Chemistry | Office | 299 | 34 | $4.20 | $1,256 |
| 93356 Echocardiography (TTE/TEE) | Office | 254 | 246 | $28.24 | $7,172 |
| A9555 Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 159 | 149 | $270.45 | $43K |
| 78431 Myocardial Perfusion Scan | Office | 150 | 149 | $1,775.48 | $266K |
| 78434 Myocardial Perfusion Scan | Office | 149 | 149 | $403.21 | $60K |
| 93015 Electrocardiogram | Office | 147 | 147 | $54.36 | $7,991 |
By year: 2022 $789K for 10,311 services; 2023 $847K for 10,676 services; 2024 $865K for 10,727 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 299 | 34 | $4.20 | $1,256 |
Medicare prescription drug claims, 2024
In 2024, the drug Joel C Osborn prescribed most often to Medicare patients was Eliquis (Apixaban), with 1,197 prescriptions and refills. In total Joel C Osborn wrote 12,337 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 1,197 | 1,951 | 246 | $1.1M |
| Metoprolol Succinate Generic | 890 | 1,980 | 236 | $13K |
| Losartan Potassium Generic | 686 | 1,635 | 178 | $6,939 |
| Atorvastatin Calcium Generic | 648 | 1,736 | 197 | $5,224 |
| Carvedilol Generic | 585 | 1,285 | 150 | $4,199 |
| Clopidogrel Clopidogrel Bisulfate | 583 | 1,479 | 181 | $6,459 |
| Sotalol Sotalol Hcl | 567 | 1,161 | 139 | $9,248 |
| Furosemide Generic | 556 | 1,209 | 182 | $2,826 |
| Metoprolol Tartrate Generic | 495 | 1,230 | 142 | $3,658 |
| Potassium Chloride Generic | 430 | 999 | 131 | $9,449 |
| Lisinopril Generic | 371 | 1,002 | 111 | $3,181 |
| Rosuvastatin Calcium Generic | 356 | 872 | 93 | $4,379 |
| Spironolactone Generic | 336 | 741 | 95 | $2,980 |
| Hydrochlorothiazide Generic | 295 | 767 | 89 | $1,328 |
| Amlodipine Besylate Generic | 284 | 692 | 89 | $1,847 |
Brand drugs: 2,072 claims; generic drugs: 10,265 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Joel C Osborn $69.99 ($69.99 in general payments such as food, travel and fees) from 2 companies. The largest payer was Boston Scientific Corporation with $47.51.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.